Press Releases

Date Title
3/8/22 Sarepta Therapeutics anuncia quinto año de Route 79, El Programa de Becas Duchenne
3/2/22 Sarepta Therapeutics to Present at Upcoming Investor Conferences
3/1/22 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments
2/28/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/22/22 Sarepta Therapeutics Announces the Launch of SareptaCircle to Highlight the Experiences of Individuals and Families Living with Rare Disease
2/22/22 Sarepta Therapeutics anuncia el lanzamiento de SareptaCircle para destacar las experiencias de personas y familias que viven con enfermedades raras
2/22/22 Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022
2/1/22 Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases
1/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/10/22 Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy
Displaying 51 - 60 of 768